Fortis Therapeutics Raises $40M in Series A Funding

– Fortis Therapeutics from San Diego is developing novel antibody-drug conjugate FOR46 for late-stage multiple myeloma and metastatic castration-resistant prostate cancer.
– The company closed a $40m Series A financing cofunded by Avalon Ventures, Bregua Corporation, Lilly Asia Ventures, Osage University Partners, Vivo Capital, the Myeloma Investment Fund, the venture philanthropy fund of the Multiple Myeloma Research Foundation (MMRF), and Fulcrum 2020, LLC.
– The new investment will be used to advance FOR46 in clinical trials for the treatment of relapsed or refractory multiple myeloma and metastatic castration-resistant prostate cancer.